NeuroVectis is a planned Matricelf subsidiary focused on developing a regenerative therapy for Parkinson’s disease and Parkinsonism. The program is intended to use patient-derived cells, extracellular matrix, hydrogel, and engineered neural tissue to create a living implant designed to restore dopamine production and support brain-tissue repair, rather than only manage symptoms.
Cumulative Funding Raised Over Time ($)
Employees Over Time
NeuroVectis Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Feb 24, 2026
www.ynetnews.com
Matricelf launches Parkinson’s spin-off to develop living brain implants
null
Feb 24, 2026
www.news1.co.il
מטריסלף מקימה חברת-בת לטיפול בפרקינסון ומגייסת 3.5 מיליון דולר
null
Feb 23, 2026
tv10.co.il
מטריסלף מקימה חברה בת לפיתוח ומסחור של פתרון רפואי לפרקינסון